All In Biotech

Drug Trial Radar · NCT02109185

A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers

A Randomized, Double-Blind, Multiple-Dose Trial of Mometasone Nasal Spray, 50 μg (Mylan), Nasonex® Nasal Spray, 50 μg (MSD-US), Nasonex® Nasal Spray Suspension, 50 μg (MSD-EU) & Placebo for Treatment of the Signs & Symptoms of Seasonal Allergic Rhinitis in 1,520 Male & Female Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,307

Actual

Start

Sep 2013

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Mylan Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Apr 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare the safety and efficacy of a generic mometasone nasal spray to the reference listed drugs in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations will be tested for superiority against a placebo nasal spray.

Conditions

  • Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis

Interventions

  • Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.Drug

  • Nasonex® Nasal Spray, 50 μg/actuationDrug

  • Nasonex® Nasal Spray Suspnsn, 50 μg/actuationDrug

  • Placebo Nasal Spray, 50 μL/actuationDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from Baseline of the mean reflective Total Nasal Symptom Score (rTNSS)Time frame: 14 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.